Meropenem
- Generic Name
- Meropenem
- Brand Names
- Vabomere
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O5S
- CAS Number
- 96036-03-2
- Unique Ingredient Identifier
- YOP6PX0BAO
- Background
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
...
- Indication
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, vi...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
- Associated Therapies
- -
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
- Conditions
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 1000
- Registration Number
- NCT05355350
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Beilinson Hospital, Petah tikva, Israel
🇮🇱Sheba Tel HaShomer Medical Campus, Ramat Gan, Israel
To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05340530
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sumitovant Biopharma, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT05226923
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)
- Conditions
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Evopoint Biosciences Inc.
- Target Recruit Count
- 780
- Registration Number
- NCT05204368
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
PK of Meropenem in Patients on Plasma Exchange
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Prince of Songkla University
- Target Recruit Count
- 15
- Registration Number
- NCT05042271
- Locations
- 🇹🇭
Faculty of Medicine, Prince of Songkla University, Thailand, Hat Yai, Songkla, Thailand
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04983901
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Wockhardt
- Target Recruit Count
- 528
- Registration Number
- NCT04979806
- Locations
- 🇲🇽
Guadalajara, Guadalajara, Mexico
🇮🇳Chandigarh, Chandigarh, Punjab, India
🇺🇸Chula Vista, Chula Vista, California, United States
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 13
- Registration Number
- NCT04876430
- Locations
- 🇧🇷
Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
🇧🇷Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Antibiotics Continuous Infusion at Home
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- Ospedale San Carlo Borromeo
- Target Recruit Count
- 50
- Registration Number
- NCT04816968
- Locations
- 🇮🇹
ASST Santi Paolo Carlo - San Carlo Borromeo Hospital - SSd Onco-Hematology, Milan, Italy
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- King Abdul Aziz Specialist Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04553367
- Locations
- 🇸🇦
King abd el Aziz specialist hospital, Ta'if, Saudi Arabia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.